The pharmaceutical company Eli Lilly plans to lay off 1,000 of its U.S. sales representatives in a "major restructuring," a source familiar with the plan said.
The layoffs constitute about a 30-percent reduction in the company's U.S. Bio-Medicines sales force, the source said.
Lilly, based in Indianapolis, Ind., is preparing for pending patent losses of key drugs Cymbalta, an antidepressant, and Evista, an osteoporosis medicine.
The patent on Cymbalta, one of Lilly's biggest sellers, is expected to expire this December along with several other patents Lilly currently owns. Evista's patent is set to expire in March 2014.